<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; NeurogesX Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/neurogesx-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(NGSX) NeurogesX &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2009/11/18/ngsx-neurogesx-bull-of-the-day/20832</link>
		<comments>http://www.stockbloghub.com/2009/11/18/ngsx-neurogesx-bull-of-the-day/20832#comments</comments>
		<pubDate>Wed, 18 Nov 2009 17:34:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[NeurogesX Inc]]></category>
		<category><![CDATA[NGSX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20832</guid>
		<description><![CDATA[NeurogesX (NGSX) received some very good news this week when the U.S. FDA approved Qutenza for the management of postherpetic neuralgia (PHN). Management will now move forward with preparing for the commercial launch during the first half of 2010. Securing reimbursement and hiring the sales force remain the next biggest hurdles for the company. However, with approval now complete and the financial position solid ($57 million in cash on hand), we remain very position on the NeurogesX story. We recommend accumulating the stock at today&#8217;s level up to $12 per share. Our rating is Outperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/18/ngsx-neurogesx-bull-of-the-day/20832/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NGSX) NeurogesX Wins Big FDA Approval for Qutenza</title>
		<link>http://www.stockbloghub.com/2009/11/17/ngsx-neurogesx-wins-big-fda-approval-for-qutenza/20754</link>
		<comments>http://www.stockbloghub.com/2009/11/17/ngsx-neurogesx-wins-big-fda-approval-for-qutenza/20754#comments</comments>
		<pubDate>Tue, 17 Nov 2009 14:53:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[NeurogesX Inc]]></category>
		<category><![CDATA[NGSX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20754</guid>
		<description><![CDATA[FDA Approves NeurogesX&#8217;s Qutenza After the market closed on November 16, 2009, NeurogesX (NGSX) announced that the U.S. FDA had approved Qutenza (capsaicin patch) for the management of neuropathic pain due to postherpetic neuralgia (PHN).  We expect management to spend the next several months preparing for the launch by facilitating reimbursement procedure, establishing distribution channels, hiring and training the specialty sales force, and conducting the manufacturing for commercial supply. Key to our bullish sales forecast for the drug will be establishing a permanent reimbursement code for both the product and application, as Qutenza requires administration by a physician or healthcare professional. Qutenza is a cutaneous (skin) patch designed to treat peripheral neuropathic pain conditions. The Qutenza patch provides a pure high concentration (8%) of a synthetic capsaicin, known as trans­-capsaicin, directly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/17/ngsx-neurogesx-wins-big-fda-approval-for-qutenza/20754/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

